Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26107457 | 0.87 | KDM1A (0.67) | KDM1A | |
| SCHEMBL21460366 | 0.85 | KDM1A (0.53) | KDM1A | |
| SCHEMBL21460363 | 0.85 | KDM1A (0.53) | KDM1A | |
| SCHEMBL28392417 | 0.85 | KDM1A (0.79) | KDM1A | |
| SCHEMBL20067667 | 0.85 | SMN1; SMN2 (0.65) | KDM1A | |
| SCHEMBL20067709 | 0.85 | SMN1; SMN2 (0.65) | KDM1A | |
| SCHEMBL13423695 | 0.83 | PDK2 (0.53) | KDM1A | |
| SCHEMBL3218302 | 0.83 | PDK2 (0.53) | KDM1A | |
| SCHEMBL3218307 | 0.83 | SMN1; SMN2 (0.51) | — | |
| SCHEMBL14275541 | 0.81 | HPGD (0.60) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | claimed |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | KDM1A 4019/4885 |
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | KDM1A 798/4885 |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | KDM1A 4019/4885 |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | TP53, VHL, RB1 | KDM1A 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.